Atossa Therapeutics, Inc. (NasdaqCM: ATOS)
Health Care · Biotechnology · US
$2.65
-1.12% today · -77.2% 1Y
Atossa Therapeutics, Inc. (NasdaqCM: ATOS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $26.45M and employs 16 people.
Over the last twelve months the share price has lost 77.2%, trading between 1.70 and 19.35.
Tweenvest scores Atossa Therapeutics, Inc. across four factors: quality 26/100. Its strongest factor is quality.
ATOS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $26.45M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -4.34
- Dividend yield
- —
- Beta (5Y)
- 1.25
- 52-week high
- $19.35
- 52-week low
- $1.70
- Avg volume (3M)
- —
- Shares outstanding
- 9.98M
- Employees
- 16
- Next earnings
- —
About Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.
- ISIN
- US04962H7044
- Founded
- 2019
- Listed since
- Nov 8, 2012
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $464.58B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $238.06B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $183.64B | $148.09 | -0.01% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.72B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $81.36B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $65.40B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $59.75B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.19B | AU$172.44 | -0.69% |
Figures last refreshed Aug 18, 2026.